KEGG   DRUG: CatumaxomabHelp
Entry
D09207                      Drug                                   

Name
Catumaxomab (INN);
Removab (TN)
Remark
ATC code: 
Activity
Antineoplastic, Anti-CD3 antibody, Anti-EpCAM antibody
  Disease
Malignant ascites
Comment
Monoclonal antibody
Target
  Pathway
Hematopoietic cell lineage
T cell receptor signaling pathway
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01X OTHER ANTINEOPLASTIC AGENTS
    L01XC Monoclonal antibodies
     L01XC09 Catumaxomab
      D09207  Catumaxomab (INN)
Target-based classification of drugs [BR:br08310]
 Others
  Cellular antigens
   CD3
    Catumaxomab
     D09207  Catumaxomab (INN)
   CD326 (EpCAM)
    Catumaxomab
     D09207  Catumaxomab (INN)
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D09207
BRITE hierarchy
Other DBs
CAS: 
509077-98-9
PubChem: 

» Japanese version   » Back

DBGET integrated database retrieval system